中国药科大学副研究员，海洋药学硕士生导师。中国药科大学微生物与生化药学专业，获博士学位。致力于探讨非编码RNA及其来源的新型微肽在疾病发生发展中的功能与机制，发现人体内源性微肽，并对其进行改造优化、提高成药性，开发成FIC多肽药物，为这些疾病的诊断和治疗提供了新的用药策略。长期从事抗肿瘤和抗类风湿等多肽新药的临床前研发工作，获得新药临床批件2件。曾在Signal Transduct Target Ther（IF：38.104）、J Am Chem Soc（IF：16.383）、Acta Pharm Sin B（14.903）、Mol Ther Nucleic Acids（IF：10.183）、Cell Death Dis（IF：9.685）和Oncogene（IF：8.756）等杂志发表多篇论文，第一作者累计影响因子为100分以上；申请中国发明专利两项，授权一项；获中国产学研合作创新成果奖二等奖、第六届江苏医药科技进步奖二等奖。
| 多肽药物研发 |
1）参与完成化学药品一类抗肿瘤药物——安替安吉肽的临床前研究，并获得药物临床试验批件，批件号：2013L01914；
2）参与完成化学药品一类抗类风湿药物——派格安替安吉肽的临床前研究，并获得药物临床试验批件，批件号：2018L02321；
3）主持中国博士后科学基金面上项目，2017M621884，长链非编码RNA HOTTIP促进食管鳞癌转移的机制研究；
4）作为主要骨干人员参与国家“重大新药创制”科技重大专项：一类抗类风湿新药派格安替安吉肽的临床试验研究及关键技术开发，课题编号：2019ZX09301124。
1）Wang Y, Li M, Xu H*, et al. Natural killer cell-derived exosomal miR-1249-3p attenuates insulin resistance and inflammation in mouse models of type 2 diabetes, Signal Transduct Target Ther, 2021, 6(1): 409. (IF=38.104)
2）Wang Y, Lu J, Xu H*, et al. Tumor-derived EV-encapsulated miR-181b-5p induces angiogenesis to foster tumorigenesis and metastasis of ESCC, Molecular Therapy - Nucleic Acids, 2020, 20: 421-437. (IF=10.183)
3）Wang Y, Li D, Xu H*, et al. Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma, Cell Death and Disease, 2020, 11(8): 664. (IF=9.685)
4）Yang P, Wang Y, Xu H*, et al. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide, Journal of the American Chemical Society. 2020, 142(44): 18874-18885. (IF=16.383，共一作者)
5）Li M, Wang Y, Xu H*, et al. Integrins as attractive targets for cancer therapeutics, Acta Pharmaceutica Sinica B, 2021, 11(9): 2726-2737. (IF=14.903，共一作者)
6）Lin C, Wang Y, Guo C, Xu H*, et al. Transcriptional and posttranscriptional regulation of HOXA13 by lncRNA HOTTIP facilitates tumorigenesis and metastasis in esophageal squamous carcinoma cells, Oncogene, 2017, 36(38): 5392-5406. (IF=8.756，共一作者)
7）Li D, Wang Y, Xu H*, Hu J*, et al. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice, Journal of Neuroinflammation, 2020, 17(1): 126. (IF=9.587，共一作者)
8）Li D, Wang Y, Xu H*, Hu J*, et al. CD200-CD200R1 signalling attenuates imiquimod-induced psoriatic inflammation by inhibiting the activation of skin inflammatory macrophages, International Immunopharmacology, 2020, 78: 106046. (IF=5.714，共一作者)
9）Xia C, Wang Y, Xu H*, et al. Novel Peptide CM 7 Targeted c-Met with Antitumor Activity, Molecules, 2020, 25(3): 451-470. (IF=4.927，共一作者)
10）Wang X, Wang Y, Hu J*, Xu H*. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity, Cancer Medicine, 2021, 10(6): 2125-2136. (IF=4.711，共一作者)
